Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-1020 Extension Study in Schizophrenia
NCT00722176Phase 2Completed
- Sponsor
- BioLineRx Ltd.
- Start
- Jun 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BL-1020 in schizophrenia (3 arms), sponsored by BioLineRx Ltd. Primary endpoint: Changes from baseline in vital signs, laboratory and ECG evaluations, physical/neurological examination, Extrapyramidal Symptom Rating Scale (ESRS), and incidence of adverse events (AEs) and adverse… at 6 weeks. Started Jun 2008; status: completed.
02
Drugs
BL-1020
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00722176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00722176.